Translating gastric cancer genomics into targeted therapies

Publication date: April 2016
Source:Critical Reviews in Oncology/Hematology, Volume 100
Author(s): Yvonne L.E. Ang, Wei Peng Yong, Patrick Tan
Gastric cancer is a common disease with limited treatment options and a poor prognosis. Many gastric cancers harbour potentially actionable targets, including over-expression and mutations in tyrosine kinase pathways. Agents have been developed against these targets with varying success- in particular, the use of trastuzumab in HER2-overexpressing gastric cancers has resulted in overall survival benefits. Gastric cancers also have high levels of somatic mutations, making them candidates for immunotherapy; early work in this field has been promising. Recent advances in whole genome and multi-platform sequencing have driven the development of molecular classification systems, which may in turn guide the selection of patients for targeted treatment. Moving forward, challenges will include the development of appropriate biomarkers to predict responses to targeted therapy, and the application of new molecular classifications into trial development and clinical practice.



from Cancer via ola Kala on Inoreader http://ift.tt/1KuwqgS
via IFTTT